Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Genmab Q2 Loss Narrows

Denmark-based Genmab A/S (GNMSF.PK), Wednesday reported second-quarter net loss of 2.1 million Danish krone or 0.05 krone per share, compared to 80.6 million krone or 1.79 krone per share last year.

Net earnings from continuing operations for the quarter was 8.0 million krone or 0.18 krone per share, compared to net loss from continuing operations of 71.4 million krone or 1.59 krone per share last year.

Net revenues for the quarter was 111.6 million krone, up from 83.9 million krone last year.

The company net loss for the first half of 2012 was 71.6 million krone or 1.59 krone per share, compared to 191.8 million krone or 4.27 krone per share last year.

Net loss from continuing operations for the period was 51.8 million krone or 1.15 krone per share, compared to 172.7 million krone or 3.84 krone per share last year.

Genmab's revenues for the first half period grew 23 percent to 206 million krone from 167 million krone in the prior year period, driven mainly by higher Arzerra royalties and the achievement of a milestone under our collaboration with GlaxoSmithKline.

Click here to receive FREE breaking news email alerts for GENMAB A/S DKK and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.